Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24698805 | 0.79 | CYP1A2 (0.34) | HTR2AHTR2CHTR2BCYP1A2CYP2C19 | |
| SCHEMBL24373469 | 0.68 | HRH3 (0.46) | HRH2HRH3 | |
| SCHEMBL24697559 | 0.68 | HTR2A (0.35) | HTR2AHTR2CHTR2BCYP1A2CYP2C19 | |
| SCHEMBL856157 | 0.67 | CYP1A2 (0.44) | HTR2AHTR2CHTR2BCYP1A2CYP2C19 | |
| SCHEMBL25403539 | 0.66 | PDE10A (0.39) | HTR2AHTR2CHTR2BCYP1A2CYP2C19 | |
| SCHEMBL857098 | 0.66 | KMT2A (0.46) | HTR2AHTR2CHTR2BCYP1A2CYP2C19 | |
| SCHEMBL23960180 | 0.66 | HRH2 (0.34) | HRH2HRH3 | |
| SCHEMBL22282198 | 0.65 | HRH3 (0.38) | HRH2HRH3 | |
| SCHEMBL16637692 | 0.64 | HTR2A (0.38) | HTR2AHTR2CHTR2BCYP1A2CYP2C19 | |
| SCHEMBL4899939 | 0.64 | HTR2A (0.38) | HTR2AHTR2CHTR2BCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | KHK, GCK, HK1 | HTR2A 3764/4885HTR2C 2955/4885HTR2B 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.